Ameriprise Financial Inc Immunovant, Inc. Transaction History

Ameriprise Financial Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$25.1 - $31.61 $90,560 - $114,048	-3,608 Reduced 18.6%	15,793 $416,000
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $174,082 - $251,836	5,751 Added 42.13%	19,401 $626,000
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $129,811 - $183,211	4,146 Added 43.62%	13,650 $575,000
Q3 2023 Nov 14, 2023	SELL	$18.55 - $39.96 $36,914 - $79,520	-1,990 Reduced 17.31%	9,504 $364,000
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $4,260 - $7,125	300 Added 2.68%	11,494 $218,000
Q1 2023 May 15, 2023	SELL	$15.27 - $19.72 $24,813 - $32,044	-1,625 Reduced 12.68%	11,194 $173,000
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $84,477 - $227,537	12,819 New	12,819 $227,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.